The numbers moving through India's hospital M&A market right now are striking. 

In the two-year period between 2022 and 2024 alone, India's healthcare and pharma sector saw over 594 M&A and PE transactions worth more than USD 30 billion. The hospital segment accounted for a significant share of that, with deal values running at 20 to 30 times EBITDA in high-demand specialties like oncology, cardiology, and mother-and-child care. 

Global PE firms are competing for India’s hospital sector. In mid-2025, the race for a stake in Cloudnine Hospitals drew binding bids from six of the world's largest funds simultaneously. 

The momentum is high. The capital is available. And the pressure to move quickly, before the next bidder locks in, is very much part of the environment. 

That pressure is also where many deals start going wrong. 

Why Healthcare M&A Is Different From Every Other Sector

 

A hospital acquisition is not a standard corporate transaction with a healthcare label on it. The regulatory framework, the operational dependencies, the talent considerations, and the cultural dynamics of a clinical institution make it materially different from acquiring a manufacturing unit, a retail chain, or even a pharma company. 

Most experienced dealmakers know this in principle. Many of them still underestimate it in practice. 

The legal and regulatory complexity alone is substantial. Just the visible layer includes: 

For any deal involving foreign investment, FEMA compliance, FDI routing, and Competition Commission of India filings under the new deal value thresholds added by the Competition Amendment Act 2023 add further dimensions. 

And for transactions involving government-allotted or concessional land (which applies to a significant proportion of Indian hospital facilities) the due diligence extends into allotment letters, lease deeds, restrictions on transfer, and obligations to serve economically weaker sections. These are not items that surface in standard financial reviews. They are, however, items that can determine whether a deal closes cleanly or stalls for months in regulatory clarification. 

The Clinical Considerations That Financial Models Miss 

Beyond compliance, there is a class of diligence risk in hospital M&A that is uniquely clinical in nature and genuinely invisible to teams that approach the deal through a purely financial or legal lens. 

The senior clinical team problem 

In many Indian hospitals, the senior doctors are not salaried employees. They operate as retainers or consultants, often with informal arrangements that have evolved over years. Their continued engagement post-acquisition is not guaranteed. Their loyalty is typically to the institution's clinical culture and to the professional relationships they have built there. 

A deal that looks compelling on paper (strong patient volumes, clean financials, solid EBITDA) can see its core value proposition walk out the door within twelve months of closing if the transition unsettles the senior clinical team. Valuation multiples in Indian hospital deals partly reflect the quality of the people running clinical operations. When those people are not accounted for in the deal structure, the multiple does not hold. 

The accreditation question 

NABH or JCI accreditation status deserves attention. Accreditation is an ongoing operational commitment. 

Hospitals that have achieved accreditation and allowed their systems to drift face reinvestigation, gap assessments, and the full compliance burden all over again. For an acquirer, understanding whether the target's accreditation reflects genuine operational quality or a one-time compliance effort is a meaningful distinction. 

The Post-Acquisition Reality That Blindsides Most Buyers

 

The hard work begins on day one of operation under new ownership. 

Post-merger integration in hospital settings involves: 

 

These dynamics resist the kind of rapid standardisation that works well in other sectors. 

A consistent finding in healthcare M&A research: deals in which operational integration was rigorously planned outperformed those where it was treated as a post-deal problem. In hospitals, this extends well beyond IT systems to people and protocols. The integration plan is not separate from the deal structure. It should inform it. 

What the Best Deals Have in Common 

Looking at the transactions that have performed well a few things stand out beyond the financial profile of the targets. 

The acquirers had sector-specific intelligence, not just sector-level knowledge. They understood: 

 

The financial model was built on that foundation. 

They also moved with the right advisors: people who understood both the clinical and commercial sides of the transaction. Healthcare M&A in India sits at the intersection of clinical operations, real estate, regulatory compliance, talent strategy, and financial structuring. A team that is strong in two of those areas and light on the others will find the gaps eventually. Usually after the deal is done. 

Before the Handshake 

If you are approaching a hospital acquisition, a minority investment in a healthcare platform, or a PE entry into the sector, the question worth asking before you structure the deal is: how complete is your picture? 

Financial modelling is not the answer on its own. The numbers are downstream of clinical quality, regulatory standing, talent stability, and operational systems. Getting those right is what the numbers eventually reflect. 

Candid Health works with investors, PE firms, and acquirers navigating India's healthcare M&A landscape: bringing together clinical intelligence, sector relationships, and deal advisory under one relationship.  

If you are in the early stages of a transaction or evaluating an opportunity, a candid conversation is a good place to start. Reach out to us.